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SUMMARY
In humans, Vg9Vd2 T cells respond to self and
pathogen-associated, diphosphate-containing iso-
prenoids, also known as phosphoantigens (pAgs).
However, activation and homeostasis of Vg9Vd2
T cells remain incompletely understood. Here, we
show that pAgs induced expression of the ecto-
ATPase CD39, which, however, not only hydrolyzed
ATP but also abrogated the gd T cell receptor (TCR)
agonistic activity of self and microbial pAgs (C5
to C15). Only mevalonate-derived geranylgeranyl
diphosphate (GGPP, C20) resisted CD39-mediated
hydrolysis and acted as a regulator of CD39 expres-
sion and activity. GGPP enhanced macrophage dif-
ferentiation in response to the tissue stress cytokine
interleukin-15. In addition, GGPP-imprinted macro-
phage-like cells displayed increased capacity to pro-
duce IL-1b as well as the chemokine CCL2 and pref-
erentially activated CD161-expressing CD4+ T cells
in an innate-like manner. Our studies reveal a previ-
ously unrecognized immunoregulatory function of
CD39 and highlight a particular role of GGPP among
pAgs.
INTRODUCTION
gd T cells are unconventional T cells (Godfrey et al., 2015) that
constitute a first line of defense against pathogens and tumors
(Chien et al., 2014; Kabelitz et al., 2013; Vantourout and Hayday,
2013). gd T cells can be classified according to their expression
of T cell receptor (TCR) variable (V) region segments (Kabelitz
and He, 2012). Whereas Vd1 T cells reside in epithelial tissues
and join the battle against viruses, fungi, and tumor cells, Vd2
T cells co-expressing Vg9 are the major gd T cell population in
adult human blood. Although Vg9Vd2 T cells represent a minority
among all T cells (<10%), their frequency in the blood of patients
may rise significantly during infections (up to 60% of total T cells)
(Chien et al., 2014). The Vg9Vd2 TCR functions as a pattern
recognition receptor to detect self and pathogen-associated
phosphoantigens (pAgs), which are organic molecules often
consisting of one or more C5 isoprene units and a diphosphate
group (also known as the pyrophosphate group) (Bonneville
et al., 2010; Thurnher and Gruenbacher, 2015). Butyrophilin
3A1 (BTN3A1) has recently been reported to bind pAgs and
mediate activation of Vg9Vd2 T cells (Harly et al., 2012; Sand-
strom et al., 2014; Vavassori et al., 2013; Wang et al., 2011).
Vg9Vd2 T cells have long been considered to be primate specific
as they do not exist in mice. However, the genes encoding Vg9,
Vd2, and BTN3A1 have been found to be co-conserved across a
variety of placental mammals (Karunakaran et al., 2014).
In tumor cells, pAgs frequently accumulate due to a dysre-
gulated mevalonate pathway (Thurnher and Gruenbacher,
2015; Thurnher et al., 2012). Nitrogen-containing bisphospho-
nates (N-BPs) such as zoledronate inhibit a key enzyme of the
mevalonate pathway and thus induce accumulation of isopen-
tenyl diphosphate (IPP), a prototypic Vg9Vd2 T cell pAg, which
is also produced by microbial pathogens including mycobac-
teria via the non-mevalonate pathway of isoprenoid biosyn-
thesis. Consistent with their ability to perform innate-like re-
sponses, Vg9Vd2 T cells express CD161 (KLRB1) and the
transcription factors T-bet and eomesodermin (Dimova et al.,
2015; Fergusson et al., 2014; Gruenbacher et al., 2014; Ribot
et al., 2014).
gd T cells have promising anti-tumor potential (Silva-Santos
et al., 2015). In a recent study, which integrated tumor gene
expression profiles and overall survival data from nearly 18,000
patients, intra-tumoral gd T cell signatures emerged as the
most significant favorable cancer-wide prognostic population,
and at the molecular level, CD161 has been identified as the
top favorable pan-cancer prognostic gene (Gentles et al.,
2015). Both indirect and direct evidence for the anti-leukemic po-
tential of gd T cells have also been obtained (Airoldi et al., 2015;
Godder et al., 2007; Wilhelm et al., 2014).
Inflammatory and immune responses are associated with the
controlled or lytic release of nucleotides, particularly ATP (Idzko
et al., 2014). Extracellular ATP can function as a potent signaling
molecule through triggering of purinergic P2 receptors (P2Rs)
(Burnstock and Boeynaems, 2014; Eltzschig et al., 2012). Given
the biological potency of ATP, the control of the duration and
magnitude of the cellular responses to ATP is crucial (Antonioli
et al., 2013; Dwyer et al., 2007). Therefore, immune cells either
constitutively express or upregulate CD39, an ecto-ATPase,
which converts ATP and ADP into AMP. The ecto-50-nucleo-
tidase CD73 can complete the dephosphorylation process and
convert the monophosphate into adenosine. Whereas ATP
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exerts predominantly proinflammatory effects, adenosine has
potent immunosuppressive effects (Eltzschig et al., 2012). Ge-
netic deletion of CD39 is associated with impaired ATP phos-
phohydrolysis (Enjyoji et al., 1999). Increased CD39 expression
in T cells with age has been reported to promote T cell apoptosis
and to contribute to impaired vaccine responses in older individ-
uals (Fang et al., 2016). Although CD39 is considered to be an
activation marker of B and T cells (Dombrowski et al., 1998;
Dwyer et al., 2007), Vg9Vd2 T-cell-associated CD39 has not
been reported so far. In the present work, we therefore sought
to examine expression and function of CD39 in Vg9Vd2 T cell
activation and homeostasis and provide evidence that CD39
serves a previously unrecognized purpose.
RESULTS
pAgs Induce Expression of the Ecto-ATPase CD39 on
Vg9Vd2 T Cells
To examine whether CD39 is upregulated during Vg9Vd2 T cell
activation by mevalonate-derived pAgs (Figures 1A and 1B),
we combined CD39 cell surface staining with intracellular IFN-
g detection. Data shown in Figure 1C demonstrate that freshly
isolated Vg9Vd2 T cells (day 0) lacked CD39 expression.
Vg9Vd2 T cells produced IFN-g early (day 1) in response to
pAg plus interleukin-2 (IL-2), whereas CD39 upregulation was
clearly delayed and started only on day 3. Treatment with various
mevalonate-derived pAgs with isoprenoid chain lengths ranging
Figure 1. Mevalonate-Derived pAgs Induce Early IFN-g and Delayed CD39 Expression in Vg9Vd2 T Cells
(A) pAg generation in the mevalonate pathway: HMG-CoA reductase, the target of statins, generates mevalonate (MEV). Two kinases and a decarboxylase
convert mevalonate into IPP. An isomerase catalyzes the interconversion of IPP and its isomer DMAPP. FPP synthase catalyzes sequential condensation re-
actions of DMAPP with two units of IPP to form FPP. GGPP synthase catalyzes yet another condensation reaction with IPP to form GGPP. FPP and GGPP serve
as activated isoprenoid donor substrates in posttranslational protein prenylation. By inhibiting FPP synthase, nitrogen-containing bisphosphonates (N-BPs)
induce depletion of downstream FPP and GGPP and thus inhibition of prenylation as well as the accumulation of upstream IPP.
(B) Structures of mevalonate-derived pAgs with varying isoprenoid chain lengths (C5 to C20).
(C) IL-2 primed T cell cultures (CD3+ PBMCs) were stimulatedwith isopentenyl diphosphate (IPP, 30 mM) and then stained for surface CD3/Vd2/CD39 aswell as for
intracellular IFN-g at the times indicated. CD3+Vd2+ cells were gated and selectively analyzed for CD39 and IFN-g expression. Gates were set according to
isotype controls. A flow cytometry plot representative of two independent experiments with two different donors is shown.
(D) IL-2 primed T cell cultures (CD3+ PBMCs) were stimulated for 3 days with pAgs at either 10 mM (dark gray) or 30 mM (light gray) and then stained for surface
CD3/Vd2/CD39. CD3+Vd2+ cells were gated and selectively analyzed for CD39 expression. Isotype controls are indicated by open histograms; an experiment
representative of three experiments with three different donors is shown.
See also Figure S1.
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from C5 to C20 partially induced CD39 expression in a dose-
dependent manner within 3 days (Figure 1D). In addition, pro-
longed treatment with other Vg9Vd2 T cell agonists that induce
intracellular accumulation of pAg or mimic their presence such
as the N-BP zoledronate or antibodies against TCR Vg9 and
CD277 (BTN3A1) induced homogenous CD39 expression
(Figure S1A).
Consistent with observations in murine Vd1 T cells (Liang
et al., 2014), CD73 expression was usually weak on circu-
lating Vg9Vd2 T cells, and if nevertheless present, CD73
expression was silenced upon cell activation (Figure S1B).
To exclude the possibility that expanded CD39+ Vg9Vd2
T cells are regulatory cells, we compared the phenotypes
of expanded Vg9Vd2 T cells and regulatory T cells (Treg cells).
CD39+ Vg9Vd2 T cells expressed markers of effector cells
such as CD56 and CD161 (Fergusson et al., 2014; Gentles
et al., 2015) but lacked molecules typically associated with
Treg cells such as CD73, Foxp3, CD25, and CD152
(Figure S1C).
Figure 2. pAgs Are Substrates of CD39
(A) IL-2 primed T cell cultures (CD3+ PBMCs) were
stimulatedwith IPP in round-bottom 96-well plates
at the concentrations indicated. Cell aggregation
was documented using an Olympus CK2 micro-
scope (magnification, 4 3 10; scale bar, 500 mm)
equipped with a ProgRes CT3 digital camera and
ProgRes CapturePro 2.5 Software (Jenoptik).
(B) On day 5, IFN-g was measured in culture
supernatants.
(C) Mevalonate-derived self pAgs or pathogen-
associated pAg (HMBPP) at 10 to 50 mM (2 to
10 nmol) were incubated for 30 min at 37C with
human rCD39 (0.5 mg/ml) in 0.2 ml of 25 mM Tris,
5 mM CaCl2 (pH 7.5). Inorganic phosphate (Pi)
released during CD39-mediated hydrolysis was
measured using a colorimetric Pi assay kit. Each
pAg was measured at least three times. Controls
are ATP and ADP; at 50 mM,maximumPi release is
20 nmol for ATP and 10 nmol for ADP.
See also Figure S2.
CD39 Exhibits Isoprenoid
Diphosphate Phosphohydrolase
Activity
Mevalonate-derived pAgs share a diphos-
phate (= pyrophosphate) group with ATP
(Figure 1B). This raised the question of
whether pAgs might be substrates of the
ecto-ATPase CD39. To test this intriguing
possibility, we first used recombinant
CD39 (rCD39) and measured inorganic
phosphate (Pi) released during CD39-
mediated hydrolysis. pAgs generated in
the mevalonate pathway were tested at a
range of concentrations (10 to 50 mM)
known to induce Vg9Vd2 T cell activation
(Figures 2A and 2B) (Tanaka et al., 1995).
As expected, rCD39 effectively hydro-
lyzed ATP and ADP (Figure 2C). In addi-
tion, rCD39 hydrolyzed IPP, DMAPP, and GPP. In contrast, the
protein prenylation donor substrates FPP and geranylgeranyl
diphosphate (GGPP), which can also activate Vg9Vd2 T cells
(Gruenbacher et al., 2014; Thurnher and Gruenbacher, 2015),
were either poor substrates (FPP) or not hydrolyzed at all
(GGPP). Importantly, HMBPP (also knownasHDMAPP), ametab-
olite of the bacterial non-mevalonate pathway (Chien et al., 2014),
was also a substrate of rCD39 (Figure 2C). Whereas the artificial
pAg IPPP could also be hydrolyzed, isopentenyl monophosphate
(IP) could not be dephosphorylated by rCD39 (Figure S2A). We
also performed a side-by-side comparison of human and murine
rCD39, respectively, and observed very similar profiles of sub-
strate hydrolysis (Figure S2B).
CD39+, but Not CD39, T Cells Dephosphorylate pAgs
Next, we characterized isoprenoid diphosphate phosphohydro-
lase activity associated with expanded CD39+ Vg9Vd2 T cells
and found that these cells not only hydrolyzed ATP and ADP
but also mevalonate-derived self and pathogen-associated
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pAgs in a substrate- (Figure 3A), cell dose- (Figure 3B), and time-
dependent manner (Figure 3C). Whereas GPP was again very
susceptible to hydrolysis, GGPP remained relatively resistant.
To better attribute the observed isoprenoid diphosphate
phosphohydrolase activity to CD39, activated Vg9Vd2 T cells
were sorted into CD39+ and CD39 cells and then used side
by side as a source of isoprenoid diphosphate phosphohydro-
lase activity in the Pi release assay. CD39
+, but not CD39,
Vg9Vd2 T cells hydrolyzed ATP and ADP as well as pAgs
(Figure S2C).
To address whether CD39 is the dominant pAg-degrading
enzyme, we also compared bone-marrow-derived macro-
phages from wild-type and CD39-deficient mice (Enjyoji et al.,
1999; Robson et al., 2005). CD39+/+, but not CD39/, macro-
phages effectively degraded IPP, GPP, and ADP (Figure 3D). In
contrast, the nonself, pathogen-associated HMBPP, which is
the strongest Vg9Vd2 T cell pAg currently known, was a relatively
poor substrate of CD39 associated with murine macrophages.
CD39 is highly expressed on the surface of Foxp3+ Treg cells
(Antonioli et al., 2013; Borsellino et al., 2007). CD39+ Treg cells,
which were derived from CD4+CD25+ T cells by repetitive
stimulation with anti-CD3/CD28 antibodies in the presence of
high-dose IL-2 and rapamycin (Battaglia et al., 2006), showed
a substrate hydrolysis profile similar to that of CD39+ Vg9Vd2
T cells (Figure 3E).
CD39 Abrogates the Vg9Vd2 T Cell Stimulatory Capacity
of All pAgs Except GGPP
Next, we tested whether enzymatic hydrolysis affects the
Vg9Vd2 T cell agonistic activity of various pAgs. For this
Figure 3. CD39+, but Not CD39, Cells Degrade pAgs
(A) Expanded Vg9Vd2 T cells (day 10 to 12; >90% CD39+) were incubated for 2 hr with pAgs or ATP/ADP (10 and 30 mM = 2 and 6 nmol, respectively) in 0.2 ml of
Tris-Ringer solution (pH 7.5), containing 5 mM CaCl2. The amount of Pi released was determined using a colorimetric kit.
(B) Graded doses of CD39+ Vg9Vd2 T cells were incubated with pAgs or ADP (each at 50 mM = 10 nmol) for 0.5 hr in 0.2 ml of Tris-Ringer solution (pH 7.5),
containing 5 mM CaCl2. Pi was determined using a colorimetric kit.
(C) Graded doses of CD39+ Vg9Vd2 T cells were incubated with IPP (50 mM = 10 nmol) for 0.5 to 2 hr in 0.2 ml of Tris-Ringer solution (pH 7.5), containing 5 mM
CaCl2. Pi was quantified using a colorimetric kit.
(D) Wild-type (CD39+/+) or CD39-deficient (CD39/) macrophages (53 105 cells) grown in 24-well plates (phase contrast microscopy at 103 10 magnification;
scale bar, 200 mm). The presence or absence of CD39 expression was determined by flow cytometry. The cells were incubated with pAgs or ADP (each at
50 mM = 10 nmol) for 1 or 2 hr in 0.2 ml of Tris-Ringer solution (pH 7.5), containing 5 mM CaCl2. Pi was determined using a colorimetric kit. ***p < 0.001.
(E) Expanded Treg cells (53 10
4 cells > 60%CD39+) were incubated for 2 hr with pAgs or ATP/ADP (10, 30, and 100 mM= 2, 6, and 20 nmol, respectively) in 0.2 ml
of Tris-Ringer solution (pH 7.5), containing 5 mM CaCl2. The amount of Pi released was determined using a colorimetric kit. The data are representative of three
independent experiments and depict mean ± SEM (error bars) of triplicate measurements. See also Figure S2.
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purpose, pAgs were incubated with rCD39 or with potato
apyrase (Komoszynski and Wojtczak, 1996), an ATPase
frequently used in purinoreceptor research to neutralize the ef-
fects of extracellular ATP (Idzko et al., 2007). Isoprenoids were
separated again from the enzyme using centrifugal filtration
devices (Figure S3A).
Mock-treated pAgs induced cell aggregation (Figure S3B),
IFN-g production (Figure 4A), and Vg9Vd2 T cell expansion (Fig-
ure 4B). Pretreatment with rCD39 abolished the stimulatory ac-
tivity of all pAgs except GGPP (Figure 4; Figure S3B). Pretreat-
ment with apyrase, which has terminal phosphatase activity,
abrogated the stimulatory activity of all pAgs, including GGPP
(Figures 4A and 4B). The Vg9Vd2 T-cell-agonistic activity of the
microbial HMBPP was also abolished by rCD39 (Figure S3C).
Consistent with our observations in the Pi release assay (Fig-
ure S2B), pretreatment of pAgs with murine rCD39 also abro-
gated their ability to stimulate cytokine production as well as
Vg9Vd2 T cell expansion (Figure S4).
To simulate early upregulation of CD39, we added rCD39 on
day 1 to T cell cultures that had been stimulated with graded
doses of IPP. As a consequence, cell aggregation and IFN-g pro-
duction were clearly attenuated (Figure 4C). Collectively, the
data demonstrate that, with the exception of the relatively resis-
tant GGPP, all mevalonate-derived pAgs as well as the path-
ogen-derived HMBPP are subject to CD39-mediated hydrolysis
and that hydrolytic degradation abrogates their activity as
Vg9Vd2 T cell agonists.
GGPP Regulates ATP and pAg Breakdown
Given that pAgs can be substrates of CD39, they may compete
with ATP. Specifically, GGPP may act as a hardly hydrolyzable
competitor of ATP for CD39-mediated hydrolysis. Indeed,
Figure 4. pAgs Exposed to CD39 Fail to Stimulate Vg9Vd2 T Cell Activation
(A) pAgs with or without (= mock) ATPase (rCD39, apyrase; MW, 45–51 kDa) pretreatment were subjected to centrifugal filtration. The filtrate, which contained the
isoprenoids but not the ATPase, was used for stimulation of IL-2 primed PBMCs. IFN-g was measured in culture supernatants on day 5. See also Figure S3A.
(B) IL-2 primed PBMCs were stimulated with pAgs with or without (= mock) ATPase (rCD39 or apyrase) pretreatment followed by centrifugal filtration. The filtrate,
which contained the isoprenoids but not the ATPase, was used to induce Vg9Vd2 T cell expansion (final isoprenoid concentration, 10 mM). Absolute numbers of
Vg9Vd2 T cells in the individual cultures were derived from total cell numbers considering Vg9Vd2 T cell frequency and used to quantify Vg9Vd2 T cell expansion.
The data are representative of three independent experiments and, where applicable, depict mean ± SEM (error bars) of triplicate measurements. See also
Figures S3 and S4.
(C) IL-2 primed T cells (CD3+ PBMCs) were stimulated with IPP at the concentrations indicated with or without the addition of rCD39 (0.5 mg/ml) to the culture
medium on day 1. On day 6, IFN-g was measured in culture supernatants and cell aggregation was documented using an Olympus CK2 microscope (magni-
fication, 4 3 10). Scale bar, 500 mm.
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GGPP effectively inhibited ATP hydrolysis by rCD39 (Figure 5A).
At 10 mM, GGPP already inhibited the hydrolysis of ATP
(200 mM) by 50% and at 50 mM by 90%. Although somewhat
less effective, FPP also inhibited ATP breakdown (Figure 5B).
In contrast, farnesol (FOH) and geranylgeraniol (GGOH), the
lipophilic alcohol precursors to FPP and GGPP (Crick et al.,
1997), respectively, which lack the diphosphate group, did not
inhibit at all (Figures 5A and 5B). FPP and GGPP also prevented
ATP hydrolysis mediated by murine rCD39, and again GGPP
was more potent than FPP (Figure 5C). GGPP inhibited not
only ATP hydrolysis but also the hydrolytic degradation of
pAgs (Figure 5D). GGPP may thus increase the stability of
ATP and pAgs.
CD39 hydrolyzes both nucleotides and pAgs. By way of
analogy, CD73 might therefore be able to degrade the mono-
phosphorylated pAg that results from CD39-mediated dephos-
phorylation of the isoprenoid diphosphate. However, rCD73
hydrolyzed only AMP but not IP (Figure S2D). Moreover, IP failed
to inhibit rCD73-mediated hydrolysis of AMP.
GGPP Promotes IL-15 Driven Differentiation of
CCL2-Producing Macrophage-like Cells
The relative resistance of GGPP against CD39-mediated degra-
dation as well as its ability to regulate ATP breakdown suggested
that this pAg serves additional purposes and that it may partici-
pate in the regulation of other cell types. A blockade of CD39 on
monocytes has been shown to increase the levels of extracellular
ATP, leading to purinergic signaling and macrophage activation
(Cohen et al., 2013; Piccini et al., 2008; Sakaki et al., 2013). In
addition, GGPP has been shown to induce cellular differentiation
by increasing the expression of peroxisome proliferator acti-
vated receptor-g (PPARg) (Weivoda and Hohl, 2012), which
has also been implicated in dendritic cell (DC) development
from monocytes (Szatmari et al., 2004).
We therefore tested GGPP effects on DCs differentiated from
monocytes in the presence of IL-15 (Harris, 2011; Mohamadza-
deh et al., 2001), a cytokine known to function as a danger signal
during tissue destruction (Jabri and Abadie, 2015). Whereas
granulocyte/macrophage colony-stimulating factor (GM-CSF)
Figure 5. FPP and GGPP Prevent CD39-Mediated ATP and pAg Degradation
(A) Hydrolysis of ATP (200 mM) by rCD39 (0.5 mg/ml) was performed for 30 min at 37C in 0.2 ml of 25 mM Tris, 5 mMCaCl2 (pH 7.5) in the absence or presence of
increasing concentrations of GGPP (control GGOH), and inorganic phosphate (Pi) released during CD39-mediated hydrolysis was measured using a colorimetric
Pi assay kit. **p < 0.01, ***p < 0.001.
(B) Hydrolysis of ATP (200 mM in 0.2ml) by rCD39 (0.5 mg/ml) was performed in the absence or presence of increasing concentrations of FPP (control FOH), and Pi
production was measured using a colorimetric Pi assay kit. ***p < 0.001; see also Figure S2C.
(C) Hydrolysis of ATP (200 mM) by murine rCD39 (0.5 mg/ml) was performed in a final volume of 0.2 ml in the absence or presence of IPP, FPP, or GGPP (each at
50 mM), and Pi released during CD39-mediated hydrolysis was measured using a colorimetric Pi assay kit. **p < 0.05, ***p < 0.001.
(D) Hydrolysis of self and pathogen-associated pAgs (all at 100 mM) mediated by rCD39 (0.5 mg/ml) was performed in a final volume of 0.2 ml with or without a
15-min pre-incubation of rCD39 with GGPP (50 mM). ***p < 0.001.
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is known to stimulate the development of CD1b+ antigen-pre-
senting cells (Kasinrerk et al., 1993), IL-15 favors the differentia-
tion of DC-SIGN+ macrophages with enhanced phagocytic and
cytotoxic potential (Krutzik et al., 2005; Tel et al., 2014). In DCs
generated with GM-CSF and IL-15 (IL15-DCs), GGPP induced
CD1b/c downregulation and DC-SIGN (CD209) as well as
CD14 upregulation (Figure 6A), indicative of macrophage differ-
entiation. Furthermore, CD39 itself was consistently downregu-
lated (Figures 6A, 6B, and S5A), while ICAM-1 (CD54), which in-
teracts with LFA-1 (CD11a/CD18) to costimulate T cell activation
(Van Seventer et al., 1990), was upregulated by GGPP (Fig-
ure 6A). Although GGPP-induced phenotypic changes were
less pronounced in DCs generated with GM-CSF and IL-4 (IL4-
DCs; not shown), CD39 was also significantly downregulated
in these cells (Figure S5A).
Multiplexed bead-based cytokine analysis of culture superna-
tants revealed high levels of CCL2 in GGPP-induced macro-
phage-like cells. While the potent non-competitive P2X7 recep-
tor antagonist KN-62 only partially inhibited GGPP-induced
CCL2 production (Figure 6B), the selective PPARg antagonist
GW9662 effectively suppressed CCL2 production in a dose-
dependent manner (Figure 6C). GGPP also induced the produc-
tion of CCL2 in IL4-DCs, although less effectively, but with a
similar inhibition pattern caused by KN-62 and GW9662, respec-
tively (Figures S5C and S5D). Collectively, these data suggested
that GGPP may act by increasing ATP-mediated purinergic
signaling and by triggering PPARg-mediated effects.
GGPP-Imprinted DCs Stimulate Activation of CD161+
Effector T Cells
Both IL15-DCs (Figure 6D) and IL4-DCs (Figure S6) effectively
induced activation of IL-2 primed T cells. As little as 103
DCswere sufficient to induce substantial IFN-g and IL-17 produc-
tion, and increasing DC numbers increased the levels of
not only IFN-g and IL-17 but also IL-1b, TNF-a, IL-6, and CCL2.
At 3 3 104 DCs, IL-17, but not IFN-g, production started to
decline. Strikingly, during T cell activation, GGPP-differentiated
DCs produced higher levels of IL-1b, which is known to be critical
Figure 6. GGPP Promotes Differentiation of Macrophage-like Cells with Increased T Cell-Stimulatory Potential
(A) CD14+ monocytes (1.5 3 106/ml) were cultured in the presence of GM-CSF (800 U/ml) and IL-15 (25 ng/ml) in 96-well plates for 3 days. Cultures were
performed ± GGPP at 30 mM and DCs were subsequently stained for the surface markers indicated (MFI, mean fluorescence intensity; open histogram, isotype
controls). DC aggregation was documented by phase contrast microscopy. See also Figure S3B.
(B) CCL2 was measured in DC culture supernatants. P2X7 receptor signaling was inhibited using the non-competitive antagonist KN-62 (50 nM; IC50, 15 nM).
*p < 0.05.
(C) CCL2 was measured in DC culture supernatants and the role of PPARg was examined using the selective antagonist GW9662. *p < 0.05, **p < 0.01.
(D) Graded doses of IL15-DCs differentiated in the absence or presence of GGPP (30 mM) were cocultured with 3 3 105 T cells (CD3+ cells) in round-bottom
96-well plates for 4 days. Cytokine levels in culture supernatants were assessed using the corresponding BD CBA Flex Set. The dataset is representative of three
experiments with three different donors. *p < 0.05; see also Figure S6.
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for the differentiation of IL-17 producing T cells (Acosta-Rodri-
guez et al., 2007), and consequently, GGPP-differentiated DCs
indeed induced higher levels of IL-17 (Figure 6D; Figure S6).
Antibody-mediated neutralization of IL-1b, IL-12, or IL-18
partially inhibited IFN-g and IL-17 production, and simultaneous
neutralization of these cytokines almost completely abolished
the inflammatory response (Figure S7A). In contrast, anti-IL-15
antibody had almost no effect on IFN-g production and relatively
little effect on IL-17 production. The release of IL-1b could be in-
hibited by caspase-1 inhibitor Ac-Tyr-Val-Ala-Asp-2,6-dimethyl-
benzoyloxymethyl-ketone (YVAD) (Figure S7B), indicating that
IL-1b bioactivity depended on caspase-1-mediated processing
of the IL-1b pro-form (Lalor et al., 2011). Cell-to-cell contact
was absolutely required for IFN-g and IL-17 production (Fig-
ure S7C) as well as for the production of TNF-a, IL-1b, and IL-6
(not shown), but not for CCL2 production (Figure S7C).
CD161-expressing unconventional T cells comprising both ab
and gd T cells have recently been reported to perform such TCR-
independent, but cell-to-cell contact, responses to DC-derived
cytokines (Fergusson et al., 2014; Godfrey et al., 2015; Harris,
2011). To examine the contribution of these cells, we performed
Figure 7. DCs Imprinted by GGPP Preferen-
tially Activate CD161+ T Cells
IL4-DCs (104) or IL15-DCs (104) differentiated in
the absence or presence of GGPP (30 mM) were
washed extensively and then cocultured with
T cells (33 105) in round-bottom 96-well plates for
18 hr. Brefeldin A was added during the last 4 hr.
Cells were stained for surface CD3, CD4, CD161,
and Vd2 TCR as well as for intracellular IFN-g and
IL-17. Among CD3+ cells, Vd2 cells were gated
and selectively analyzed for CD161 and cytokine
expression (left). Among CD3+Vd2 cells, CD4+
cells were gated and selectively analyzed for
CD161 and cytokine expression (right). The data
are representative of three experiments with three
different donors. See also Figure S7.
intracellular cytokine stainings. Vg9Vd2
T cells, which made up less than 2% of
all T cells and homogenously expressed
CD161, contributed to the IFN-g
response (Figure S7D). However, the
contribution of CD4+CD161+ T cells was
more prominent (Figure 7).
DISCUSSION
The present study points toward a pre-
viously unrecognized role of human
CD39. In addition to its well-known
function as an ecto-ATPase, CD39 ex-
hibited isoprenoid diphosphate phos-
phohydrolase activity and could thus
inactivate self pAgs derived from
the potentially oncogenic mevalonate
pathway (Thurnher and Gruenbacher,
2015; Thurnher et al., 2012) as well as
the potent pathogen-associated pAg HMBPP (Chien et al.,
2014). Both ATP and isoprenoids are evolutionarily conserved
molecules, and isoprenoids are even among the oldest known
biomolecules (Brocks et al., 1999), raising the intriguing question
of who was first to serve as a substrate of CD39.
With regard to differences in the velocities of CD39-mediated
hydrolysis of nucleotides and pAgs, respectively, it is important
to consider that P2Rs and TCRs operate on different scales of
time. The fast P2XRsmay act within milliseconds because ligand
binding is directly linked to channel opening (Khakh, 2001).
P2YRs are somewhat slower and trigger upon activation sec-
ond-messenger cascades that amplify and prolong the duration
of the signal over hundreds of milliseconds or even seconds
(Khakh, 2001). By contrast, TCR-mediated T cell activation re-
quires sustained signaling over several hours (Rachmilewitz
and Lanzavecchia, 2002). Thus, in order to control magnitude
and duration of P2R- or TCR-induced responses, respectively,
CD39-mediated breakdown of nucleotides and pAgs may occur
with different kinetics.
Our finding that CD39 expression was not upregulated before
day 2 to 3, when IFN-g production already declines, is consistent
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with its regulatory role. CD39 obviously serves to degrade pAgs
in the late phase of the response and may thus contribute to the
homeostatic maintenance of Vg9Vd2 T cells. This view is sup-
ported by a previous report showing that long-lasting exposure
to supraphysiologic IPP levels produced by chronic lymphocytic
leukemia cells, especially in the absence of adequate IL-2 costi-
mulation, may lead to functional exhaustion and loss of Vg9Vd2
T cells (Coscia et al., 2012). Since ATP release and purinergic
signaling have also been implicated in T cell lineage choice
and shaping of the peripheral gd T cell compartment (Frascoli
et al., 2012), the isoprenoid diphosphate phosphohydrolase ac-
tivity of CD39 might therefore also play a role in the regulation of
Vg9Vd2 T cell development.
One important function of CD39 during interaction of antigen-
presenting cells and T cells is to rapidly degrade ATP in order to
prevent purinoreceptor desensitization (Mizumoto et al., 2002).
Along the same line, pAg degradation by CD39 that is associated
with either antigen-presenting cells or T cells may also serve to
prevent Vg9Vd2 TCR desensitization.
The phosphohydrolase activity of CD39 has been reported to
depend on the cellular activation status. Treg cells, for instance,
displayed increased CD39 activity only upon TCR-mediated
activation, while CD39 was found to be inactive on resting cells
(Borsellino et al., 2007). Although CD39 is constitutively ex-
pressed on Treg cells (Antonioli et al., 2013), CD39 expression
is also well known to be associated with effector function (Dom-
browski et al., 1998). Our observation that CD39+ Vg9Vd2 T cells
expanded with pAg and IL-2 expressed markers of innate-like
effector cells such as CD56 and CD161 but lacked molecules
associated with Treg cells such as Foxp3, CD73, CD25, and
CD152 indicated that these cells are effector and not regulatory
T cells. Specifically, absence of CD73means that CD39+ Vg9Vd2
T cells cannot convert AMP generated by CD39 into immuno-
suppressive adenosine. Conversely, the presence of CD161,
which has also been identified as a top favorable pan-cancer
prognostic gene (Gentles et al., 2015), clearly defines the effector
phenotype of CD39+ Vg9Vd2 T cells (Fergusson et al., 2014).
Although the intra- versus extracellular distribution of isopre-
noid diphosphates in various tissues has hardly been examined,
it is well established that accumulation of both exogenous and
endogenous isoprenoid diphosphates can lead to Vg9Vd2
T cell activation (Gober et al., 2003; Tanaka et al., 1995). In
contrast to ab T cells, which recognize peptide antigens in the
context of major histocompatibility complex (MHC) molecules,
it has been unknown how pAgs are presented to the Vg9Vd2
TCR. Quite recently, BTN3A1 has been identified as the elusive
cell surface molecule that can directly bind pAg for presentation
to the gd TCR (Vavassori et al., 2013).
Alternatively, pAgs accumulating in tumor cells, infected cells,
or in cells exposed to N-BPs may bind to a basic pocket within
the intracellular B30.2 domain of BTN3A1 (Sandstrom et al.,
2014). pAg binding to B30.2 may change the conformation of
the extracellular IgV domain of BTN3A1, leading to Vg9Vd2
TCR engagement (Harly et al., 2012). The B30.2 domain of
BTN3A1 may thus act as a sensor for increased intracellular
pAg levels and alert Vg9Vd2 T cells via conformational changes
of the extracellular IgV domain. In this context, it will be important
to examine whether Vg9Vd2 T-cell-stimulating cytokines such as
IL-15 and IL-18 (Gruenbacher et al., 2014) affect mevalonate
metabolism and may increase intracellular levels of isoprenoid
diphosphates, thus promoting Vg9Vd2 T cell activation.
Similar to ATP, pAgs may also be released into the extracel-
lular space. pAg release may occur during cell lysis or by more
specific mechanisms. Specific export of pAgs could be medi-
ated, for example, by ATP binding cassette transporter proteins,
which are also responsible for the export of cholesterol, a lipid
synthesized from isoprenoid diphosphates (Thurnher and
Gruenbacher, 2015). Bymembrane insertion via the hydrophobic
isoprenoid chain, these molecules may also participate in mem-
brane traffic and may thus reach the plasma membrane or may
be released from cells in the form of exosomes. Controlled or
lytic release of isoprenoid-derived pAgs into the extracellular
space can lead to direct binding of pAgs to BTN3A1 on healthy
neighboring tissue, inevitably causing collateral damage. As an
ecto-enzyme with isoprenoid diphosphate phosphohydrolase
activity, CD39 expressed by Vg9Vd2 T cells, Treg cells, or other
cells may inactivate secreted pAgs to avoid such side effects
and ensure the specific elimination of the dysregulated cells.
Consistent with such a view, anti-BTN3A1 (CD277) antibody
was the most potent stimulus of CD39 upregulation in our study.
We observed differences in the susceptibility of the various
isoprenoid diphosphates to CD39-mediated hydrolysis as well
as differences in substrate specificity between recombinant
and cell-associated CD39. Mevalonate-derived FPP (C15) and
GGPP (C20) serve as lipid donors in protein prenylation, a post-
translational modification facilitating membrane attachment of
the prenylated protein. The failure of rCD39, which lacks the
two transmembrane domains, to hydrolyze FPP and GGPP
may indicate that membrane anchoring of both the enzyme
and the C15/20 substrate is required for effective pAg hydrolysis
(Grinthal and Guidotti, 2006).
Pathogen-associated HMBPP displayed lower susceptibility
to CD39-mediated breakdown when compared to mevalo-
nate-derived self pAgs. It may indeed be this lower susceptibil-
ity of HMBPP to CD39-mediated degradation that contributes
to its high potency in stimulating Vg9Vd2 T cell activation. Me-
valonate-derived GPP, which is an intermediate during FPP
synthase-catalyzed conversion of DMAPP into FPP, appeared
to be highly susceptible to CD39-mediated hydrolysis. In
contrast, GGPP, a lipid donor in protein prenylation (Thurnher
and Gruenbacher, 2015), turned out to be relatively resistant
to CD39-mediated breakdown, indicating that this metabolite
may serve additional purposes. In the present study, we identi-
fied GGPP as a regulator of CD39 activity and expression,
which may thus increase stability of other pAgs as well as of
ATP and enhance TCR and purinoreceptor signaling. We have
previously reported that GGPP can also exhibit antioxidant ef-
fects and protect immune cells from oxidative damage (Gruen-
bacher et al., 2014). Bai et al. (2015) recently reported that CD39
expression depends on NADH oxidase-mediated generation of
reactive oxygen species (ROS). Therefore, GGPP-mediated
suppression of CD39 expression wasmost likely due to the pre-
vention of ROS effects.
Yet another effect of GGPP that we observed in our study was
the stimulation of high CCL2 production in DCs differentiated in
the presence of IL-15. Moreover, GGPP-imprinted IL15-DCs
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acquired a macrophage-like phenotype. By metabolizing GGPP,
these macrophage-like cells may contribute to the final disposal
of CD39-resistant GGPP. Both IL-15 and CCL2 are known to be
produced in response to tissue damage (Jabri and Abadie, 2015;
Matsushima et al., 1989), which inevitably results in the appear-
ance of ATP and possibly also isoprenoid diphosphates in the
extracellular space. Resistance against Mycobacterium tuber-
culosis, which is known to involve Vg9Vd2 T cells (Shen et al.,
2002), also requires CCL2 effects mediated by its receptor
CCR2, since CCR2/ mice exhibited an early defect in macro-
phage recruitment to the lung and a later defect in recruitment
of DCs and T cells to the lung (Peters et al., 2001).
Our further analyses led to the identification of a TCR-indepen-
dent response of CD161+ T cells comprising ab and gd T cells
that was almost exclusively mediated by DC-derived IL-1b, IL-
12, and IL-18. CD161 (KLRB1) has recently been reported to
be a top favorable pan-cancer prognostic gene (Gentles et al.,
2015) and a marker of enhanced innate immune characteristics
in diverse T cell subsets (Fergusson et al., 2014). The pan-cancer
prognostic significance of CD161 strongly indicates the immu-
notherapeutic potential of the family of unconventional T cells
and therefore highly recommends the use of pAg-pulsed DCs,
which may be able to link the early response of Vg9Vd2 T cells
with the subsequent response of other CD161+ unconventional
T cells.
The fact that murine CD39 exhibited similar isoprenoid diphos-
phate phosphohydrolase activity suggested that this particular
function of CD39 is not exclusively related to Vg9Vd2 T cell
biology, since this gd T cell subset does not exist in mice (Karu-
nakaran et al., 2014). CD39-mediated degradation of mevalo-
nate-derived isoprenoid diphosphates may also serve to regu-
late their function as cell-intrinsic or cell-extrinsic metabolic
cues. In transcellular lipid metabolism that has previously been
reported to occur during eicosanoid biosynthesis (Capra et al.,
2015), a lipid intermediate is synthesized and released by one
cell type and then incorporated and further metabolized by
another cell type. In accordance with such a concept, extracel-
lular isoprenoid diphosphates have previously been shown to
enter cells and contribute, for instance, to protein prenylation
(Dunn et al., 2006; Freed-Pastor et al., 2012; Thurnher and
Gruenbacher, 2015). The ability of CD39 to degrade extracellular
isoprenoid diphosphates may be crucial, since ‘‘over-prenyla-
tion’’ may lead to malignant transformation (Clendening et al.,
2010; Freed-Pastor et al., 2012).
Yet another ecto-ATPase has previously been implicated in
Vg9Vd2 T cell activation. An entity related to the mitochondrial
F1-ATPase and expressed on the tumor cell surface has been
demonstrated to promote tumor recognition by Vg9Vd2 T cells
(Scotet et al., 2005). F1-ATPase was therefore proposed to be
one of several presentation structures for pAgs (Mookerjee-
Basu et al., 2010).
In addition to its well-known function as an ecto-ATPase, the
present study identifies CD39 as an isoprenoid diphosphate
phosphohydrolase that may dephosphorylate self and path-
ogen-associated pAgs and thus abrogate Vg9Vd2 T cell re-
sponses. Only GGPP acted as a CD39 regulator and facilitated
macrophage-mediated effector T cell responses in an innate-
like manner.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies
Isoprenoids obtained from Echelon Biosciences or from Isoprenoids were
analyzed by nuclear magnetic resonance (NMR) and were at least 95%
pure. Recombinant human and murine CD39/ENTPD1 (molecular weight
[MW], 50 kDa) as well as human CD73 were from R&D. ATP, ADP, potato
apyrase, KN-62, andGW9662were obtained fromSigma-Aldrich. Zoledronate
was from Novartis Pharmaceuticals. Pamidronate (Pamidronat Dinatrium
Mayne) was obtained from Mayne Pharma. YVAD was purchased from Alexis
Biochemicals. Recombinant human cytokines were obtained as follows:
GM-CSF (LEUKINE), Berlex Laboratories; IL-2, Novartis; IL-4 (CELL GRO),
CellGenix; IL-15, PeproTech; and IL-18, Medical and Biological Laboratories
(MBL). Murine M-CSF was from Miltenyi. Monoclonal antibodies used in this
study are listed in the Supplemental Experimental Procedures.
Enzymatic Assays
pAgs (IP, IPP, IPPP, DMAPP, GPP, FPP, GGPP, HMBPP) or nucleotides (ATP,
ADP, AMP) were incubated at the concentrations indicated for 0.5 to 2 hr at
37C with rCD39 (0.5 mg/ml), rCD73 (0.5 mg/ml), or potato apyrase (10 U/ml)
in a final volume of 0.2 ml of 25 mM Tris buffer (pH 7.5), supplemented with
5 mM CaCl2. When CD39 activity associated with intact cells was measured,
Tris-Ringer (1:3) was used as buffer solution. Pi released during enzyme-medi-
ated hydrolysis of pAgs and ATP/ADP or CD73-mediated hydrolysis of AMP
was measured using the colorimetric phosphate assays kit (Abcam). The
phosphate ion forms chromogenic complex with malachite green and ammo-
nium molybdate (650 nm). The lower limit of detection was 0.1 nmol; control
values obtained with either recombinant or cell-associated enzymes or sub-
strate alone were subtracted.
Centrifugal Filtration of Isoprenoid-Derived pAgs
To study the functional consequences of pAg hydrolysis, Amicon centrifugal
filter devices with a cutoff (nominal molecular weight limit [NMWL]) of 3 kDa
(Merck Millipore: UFC500324) were used to separate the enzyme from the
lowmolecular weight isoprenoids (15min at 14,0003 g). The filtrate containing
the isoprenoid, but not the ATPase, was used for Vg9Vd2 T cell stimulation.
Human and Murine Cell Culture
All donors (n = 12) gave written informed consent in accordance with the
Declaration of Helsinki to the use of their residual buffy coats for research pur-
poses, with approval from the University Hospital of Innsbruck Review Board.
Vg9Vd2 T cell frequency in the study population was 1.92% ± 0.86 (range,
0.9%–4.0%). All cell cultures were performed in complete RPMI 1640 supple-
mented with 10% fetal bovine serum (FBS). CD3+ PBMCs were isolated using
the human Pan T cell isolation Kit (Miltenyi), and 1.5 3 106 cells/ml were stim-
ulated with IL-2 (100 U/ml) either alone or in combination with pAgs (10 to
30 mM). Whereas pAgs were added as an initial single dose, fresh IL-2 was
added every 2 to 3 days.
CD4+CD25+ T cells were isolated using the human regulatory T cell isolation
kit (Miltenyi), and Treg cultures were established by repetitive stimulation with
CD3/CD28 microbeads (T cell activation/expansion kit, Miltenyi) in the pres-
ence of IL-2 (1,000 U/ml) and rapamycin (100 nM) (Battaglia et al., 2006).
Treg cell identity and CD39 expression were confirmed by flow cytometry.
In the mixed leukocyte reaction (MLR), CD3+ cells prepared with the Pan
T cell isolation kit from Miltenyi were stimulated with graded doses of DCs in
the presence of IL-2 (100 U/ml). After co-culture, cytokines were quantified
in culture supernatants or stained intracellularly. Human DCs were generated
frommonocytes preparedwith CD14microbeads fromMiltenyi using GM-CSF
(800 U/ml) in combination with IL-15 (25 ng/ml) or IL-4 (500 U/ml) for 3 to
4 days.
To generatemurinemacrophages, bonemarrow cells frommurine tibias and
femurs of wild-type or CD39 (/) mice (Enjyoji et al., 1999; Robson et al.,
2005) were passed through a nylon mesh to remove debris, and 1 3 106 cells
were seeded in 24-well plates in 1 ml in complete RPMI 1640 supplemented
with 10% FBS and 50 ng/ml murine M-CSF. After 3 days, 1 ml of medium con-
taining all supplements was added. For flow cytometric analysis, cells were
seeded on ultra-low attachment surfaces (Corning). All experiments were
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performed according to institutional guidelines of the animal ethics committee
from the city of Freiburg.
Statistical Analyses
Experiments were always set up as triplicates and were repeated at least
two times. Group comparisons were performed using Student’s t test for
paired samples. A p value equal to or less than 0.05 was considered statisti-
cally significant. Microsoft Excel and SPSS software (SPSS) were used for
calculations.
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